nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—ADRB1—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.0636	0.065	CbGpPWpGaD
Betaxolol—ADRB2—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.0623	0.0636	CbGpPWpGaD
Betaxolol—ADRB1—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0334	0.0342	CbGpPWpGaD
Betaxolol—ADRB2—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0327	0.0334	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0225	0.023	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0221	0.0225	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.022	0.0225	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0216	0.022	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0189	0.0193	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0185	0.0189	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0185	0.0189	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0181	0.0185	CbGpPWpGaD
Betaxolol—Pindolol—HTR1B—attention deficit hyperactivity disorder	0.0137	0.647	CrCbGaD
Betaxolol—ADRB1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0134	0.0136	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0131	0.0134	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0128	0.0131	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0126	0.0128	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0124	0.0127	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0121	0.0124	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.012	0.0123	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0118	0.0121	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0118	0.012	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0117	0.0119	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0116	0.0118	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0114	0.0117	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0112	0.0115	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.011	0.0112	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0109	0.0111	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0106	0.0109	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0104	0.0107	CbGpPWpGaD
Betaxolol—ADRB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0104	0.0106	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0102	0.0104	CbGpPWpGaD
Betaxolol—CYP1A2—Methylation—COMT—attention deficit hyperactivity disorder	0.0102	0.0104	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0101	0.0103	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00994	0.0102	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00989	0.0101	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00982	0.01	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00972	0.00993	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0096	0.00981	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00914	0.00934	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00895	0.00914	CbGpPWpGaD
Betaxolol—ADRB1—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00765	0.00781	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00762	0.00778	CbGpPWpGaD
Betaxolol—Propranolol—HTR1B—attention deficit hyperactivity disorder	0.00749	0.353	CrCbGaD
Betaxolol—ADRB2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00748	0.00764	CbGpPWpGaD
Betaxolol—ADRB2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00745	0.00761	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0064	0.00654	CbGpPWpGaD
Betaxolol—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00634	0.00648	CbGpPWpGaD
Betaxolol—ADRB2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00627	0.0064	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00523	0.00534	CbGpPWpGaD
Betaxolol—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00508	0.00519	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00507	0.00518	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00434	0.00444	CbGpPWpGaD
Betaxolol—ADRB1—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00431	0.0044	CbGpPWpGaD
Betaxolol—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0043	0.00439	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00426	0.00435	CbGpPWpGaD
Betaxolol—ADRB1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00425	0.00435	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00425	0.00434	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00423	0.00432	CbGpPWpGaD
Betaxolol—ADRB2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00421	0.0043	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00416	0.00425	CbGpPWpGaD
Betaxolol—ADRB2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00416	0.00425	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00413	0.00422	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00372	0.0038	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00365	0.00372	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00364	0.00372	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00357	0.00364	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00331	0.00338	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00295	0.00301	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00289	0.00295	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00283	0.0029	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00278	0.00284	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00277	0.00283	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00272	0.00277	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00258	0.00263	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00253	0.00258	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00252	0.00258	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00247	0.00253	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0024	0.00245	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00239	0.00244	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00234	0.0024	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00234	0.00239	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00232	0.00237	CbGpPWpGaD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0023	0.00235	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00228	0.00233	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00227	0.00232	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00225	0.0023	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00223	0.00228	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00221	0.00226	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0022	0.00225	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00217	0.00222	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00216	0.00221	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00212	0.00217	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.0021	0.00214	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00205	0.0021	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00205	0.0021	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00201	0.00205	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00199	0.00203	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00195	0.002	CbGpPWpGaD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00195	0.00199	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00195	0.00199	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00193	0.00197	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00192	0.00197	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00191	0.00195	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00189	0.00193	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00188	0.00192	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.0018	0.00184	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00178	0.00182	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00176	0.0018	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00168	0.00172	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00165	0.00168	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0016	0.00164	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00157	0.0016	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00157	0.0016	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00156	0.0016	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00153	0.00157	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00153	0.00156	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00151	0.00155	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00149	0.00152	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00148	0.00151	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00147	0.0015	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00147	0.0015	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00146	0.00149	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00145	0.00149	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00144	0.00147	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00144	0.00147	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00142	0.00146	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00142	0.00145	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00139	0.00142	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00137	0.0014	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00134	0.00137	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00128	0.00131	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00128	0.00131	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00128	0.00131	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00126	0.00129	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00125	0.00128	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00123	0.00126	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00123	0.00126	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00122	0.00125	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00121	0.00124	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00109	0.00111	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00106	0.00109	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00104	0.00107	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00104	0.00106	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00103	0.00105	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.001	0.00102	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000988	0.00101	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000978	0.000999	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000966	0.000987	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000959	0.00098	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000951	0.000971	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000938	0.000959	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00093	0.00095	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000884	0.000903	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000864	0.000883	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000863	0.000882	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000859	0.000878	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000856	0.000874	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000844	0.000863	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000842	0.00086	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000841	0.00086	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00084	0.000859	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000837	0.000855	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000831	0.000849	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000825	0.000843	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000823	0.000841	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000823	0.000841	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000813	0.00083	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000807	0.000825	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000803	0.00082	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000785	0.000802	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000777	0.000794	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000774	0.000791	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000764	0.000781	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00076	0.000777	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000757	0.000774	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000755	0.000771	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000747	0.000764	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000738	0.000754	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000703	0.000718	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000688	0.000702	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000583	0.000596	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000571	0.000583	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000542	0.000554	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00053	0.000542	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00051	0.000521	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000503	0.000514	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000499	0.00051	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000492	0.000503	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000482	0.000492	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000474	0.000484	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000464	0.000474	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000459	0.000469	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000451	0.000461	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000449	0.000459	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000446	0.000455	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000441	0.000451	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000436	0.000445	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000426	0.000436	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000415	0.000424	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000406	0.000415	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000347	0.000355	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000347	0.000355	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000342	0.000349	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000318	0.000325	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000294	0.000301	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000294	0.000301	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000291	0.000297	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00029	0.000296	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000284	0.000291	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000278	0.000284	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000269	0.000275	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000264	0.00027	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000235	0.00024	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000224	0.000229	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.00021	0.000215	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000209	0.000214	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000178	0.000182	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000177	0.000181	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000172	0.000175	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000154	0.000157	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000151	0.000154	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	9.03e-05	9.22e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	7.65e-05	7.81e-05	CbGpPWpGaD
